GLP-1 Providers Using Licensed Compounding Pharmacies (2026 Verified)

The quick answer: who's most verifiable, and what lowers your risk

The providers worth your trust are the ones you can check. They name the actual pharmacy that fills your prescription, they don't pretend a compounded drug is the same as Wegovy or Ozempic, and they show the “not FDA-approved” caveat in plain sight. A low price means nothing until those three boxes are checked.

Is it legal to get a GLP-1 from a compounding pharmacy in 2026?

Sometimes — and the conditions matter. A state-licensed pharmacy can still compound semaglutide or tirzepatide for you when a licensed clinician writes a patient-specific prescriptionand the prescription fits the applicable compounding rules. But because the national shortages have ended, pharmacies are restricted from routinely making compounded versions that are “essentially copies” of FDA-approved drugs. A prescription alone is not automatic permission anymore.

For most of 2023 and 2024, brand-name GLP-1s were in shortage. When a drug is officially in shortage, pharmacies get more room to compound their own versions so patients aren't left without treatment. That's the loophole that built the whole compounded-GLP-1 industry. Then the shortages ended.

There are two legal lanes, and the difference matters:

• 503A pharmacies make medications one prescription at a time, for a specific patient. They're licensed and overseen mostly by state boards of pharmacy. This is the lane most telehealth GLP-1 programs now describe. It's still available — but a 503A pharmacy isn't supposed to regularly produce copies of a commercial drug.
• 503B outsourcing facilities are FDA-registered and make medications in larger batches under stricter federal manufacturing rules. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk ingredients these facilities are allowed to use, with public comments open through June 29, 2026.

Timeline — where things stand now:

So: possible today through a 503A pharmacy when it fits the rules — but don't treat “503A plus a prescription” as a green light. This is a story still being written, and the FDA's pen is pointed toward “closed.” That's the single biggest reason to choose a provider you can verify.

What does “licensed compounding pharmacy” really mean?

A licensed compounding pharmacy is a pharmacy that's legally allowed to mix custom medications — but “licensed” only proves the pharmacy can operate. It does not mean the medicine is FDA-approved. FDA approval applies to finished products like Wegovy, Ozempic, Zepbound, and Mounjaro. A compounded GLP-1 is a different thing, made under a different set of rules.

The FDA just warned 30 telehealth companies — here's what that means for you

In February 2026, the FDA sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1s — mainly for implying their compounded drugs were the same as FDA-approved medications, and for putting their own brand name on the product so customers couldn't tell who actually made it. A warning letter isn't a guilty verdict, but it tells you exactly which trust signals to check before you buy.

The violations fell into two buckets. First, sameness claims — marketing that suggested a compounded GLP-1 had been FDA-approved or evaluated when it hadn't. Second, hidden sourcing — putting the telehealth company's own name or trademark on the drug label without saying who actually compounded it, which falsely implies the company is the manufacturer.

The fair context: A warning letter is, in the FDA's own words, an “informal and advisory” notice — not a final finding of wrongdoing. Companies get 15 business days to respond and can fix the issues, and many do. A letter about marketing is not the same as a recall or a safety finding about the medicine. So a letter shouldn't automatically scratch a provider off your list. But it absolutely belongs in your decision: a provider that names its real pharmacy and avoids “same as Ozempic” language is doing the opposite of what got these companies warned. That's the signal worth paying for.

Are compounded GLP-1s safe? The risks worth knowing

The biggest risks aren't only about whether the pharmacy is licensed. The FDA has documented real problems with compounded GLP-1s, including dosing errors serious enough to send some people to the hospital, products shipped warm without proper refrigeration, and confusing instructions measured in “units.” Because compounded drugs aren't FDA-approved, the FDA does not review the finished product for safety, effectiveness, or quality before it's sold.

• Dosing errors. The FDA has alerted clinicians and patients about dosing mistakes with compounded injectable semaglutide — often because people aren't used to drawing medication from a vial, or because instructions use “units” and varying concentrations that are easy to misread. Some people drew up several times the intended dose and needed medical attention. Ask your provider to spell out your exact dose in milligrams and show you how it maps to the syringe.
• No FDA premarket review. Because compounded drugs aren't FDA-approved, the FDA hasn't reviewed the finished product's safety, effectiveness, or quality before marketing. Accreditation (look for PCAB) and third-party testing are stronger signals — but still don't make a compounded GLP-1 FDA-approved.
• Salt forms. The FDA has raised concerns about compounded products using salt forms of semaglutide (like semaglutide sodium or acetate) that differ from what's in the approved drug. Ask which form you're getting.
• Cold-chain handling. These medications usually need refrigeration. The FDA has flagged reports of compounded GLP-1s arriving warm. Ask what happens if your package shows up at room temperature — before you need to know.

None of this means “don't.” It means the headline price is the last thing to look at, not the first. Which brings us to the part you can actually control.

How to verify any GLP-1 compounding pharmacy before you pay

Before you pay, ask the provider for the pharmacy's name, physical address, and license type — and whether that pharmacy is licensed in your state. Then check it yourself through your state board of pharmacy and the FDA's BeSafeRx tool. If a provider won't tell you which pharmacy fills your prescription, that's your answer.

1. Get the pharmacy's name before your prescription is sent. Not “a licensed U.S. pharmacy.” The actual name.
2. Look it up with your state board of pharmacy. Every state has an online license lookup. If the pharmacy isn't listed where it should be, don't use it.
3. Confirm a real U.S. address and phone number. A legitimate pharmacy has both. (MEDVi, for example, publishes addresses for Triad Rx, RedRock, and Beaker right on its site — that's the level of detail you want.)
4. Make sure a licensed prescriber is actually involved. No prescription, no deal.
5. If they claim 503B, check the FDA's registered outsourcing facility list. Registration is public.
6. Ask about shipping and the warm-package policy — what they do if it arrives unrefrigerated.
7. Ask how your dose is measured — milligrams, milliliters, or units — and how they'll train you.
8. Screenshot everything — pricing, the pharmacy name, the cancellation policy. Future-you will be grateful.

Red flags that should stop you cold

• ✕No prescription required
• ✕Won't name the pharmacy
• ✕No U.S. address
• ✕"Generic Wegovy," "generic Ozempic," or "same as" claims
• ✕No visible "not FDA-approved" caveat
• ✕No clear cancellation or refund policy
• ✕Only takes crypto or peer-to-peer payment
• ✕Medication shows up warm or with damaged cold-chain packaging

Which GLP-1 providers using licensed compounding pharmacies are most transparent?

The most transparent providers publicly name their pharmacy partner, state plainly whether it's a 503A pharmacy or 503B facility, show the “not FDA-approved” caveat, and put pricing and cancellation terms where you can see them before checkout. Based on what we verified in June 2026, Enhance.MD and MEDVi name their pharmacies outright, while Eden, Yucca, Willow, and MyStart use general “licensed pharmacy” language.

Note on the letter column: “No” means we didn't find a February 2026 warning letter in the FDA database as of June 2026 — not a guarantee. A marketing letter doesn't prove the medicine is unsafe, but both facts earn their place in your decision.

Two providers worth a brief mention: Willow and MyStart Health both list programs starting around $299/month and describe them as fairly all-inclusive, but neither names its pharmacy partner publicly — so the same “ask for the pharmacy name” rule applies before you commit.

Does this provider use a licensed pharmacy in my state?

“Available nationwide” and “licensed in your state” are not the same promise. A provider may operate in most states while the specific pharmacy that fills your prescription is licensed only in some — so confirm both your state availability and the fill pharmacy's license in your state before you pay.

Here's how to nail this down in two minutes. First, confirm the provider treats patients in your state — read the fine print, because the gaps are oddly specific. Enhance.MD, for instance, lists availability in 40 states and names the exact ones it skips (Alabama, Arkansas, Georgia, Hawaii, Louisiana, Mississippi, Missouri, South Carolina, Tennessee, and West Virginia, as of June 2026). Second — and this is the step most people miss — ask which pharmacy will fill your prescription, then check that pharmacy's license with your own state board of pharmacy.

If your state turns out to be a gap, don't force it. An FDA-approved route is available in all 50 states through the manufacturers, and our free matching quiz can route you to an option that actually serves where you live.

Exactly what to ask each provider before you check out

A legitimate provider will answer plainly — and shouldn't make you feel unreasonable for asking where your medicine comes from. Copy and paste this into the provider's chat or email before you buy:

Question-by-question checklist:

How much do these providers cost — and the price trap

Published prices for GLP-1 providers using licensed compounding pharmacies commonly run from roughly $99 to over $320 per month, but the homepage number often isn't your real all-in cost. Separate membership fees, dose-based price jumps, and refill prices that differ from the intro offer are where budgets get blown.

The trap isn't that compounded is expensive — it's that “cheapest” and “best” aren't the same word. An intro price can climb after month one. A membership can sit beside the medication fee. Sometimes the provider that costs a little more is the one that names its pharmacy and answers your dosing questions — and that's worth paying for.

Compounded vs. FDA-approved: which route is right for you?

Choose an FDA-approved brand-name GLP-1 if you want a medication the FDA actually reviewed, if you want insurance or prior-authorization help, or if you're uneasy about compounding at all. Consider a compounded route only when a licensed clinician decides it fits your situation, you're paying cash, and you're willing to verify the pharmacy. With brand prices now lower through the manufacturers for some people, the cost gap that once made compounding an easy call can be narrower than it was.

If that's you, this is the smarter, lower-risk lane — and you don't need a compounded provider at all. One straightforward option is Ro, a telehealth service built around FDA-approved branded GLP-1s with insurance support. As of June 2026, Ro offers FDA-approved GLP-1s — including the Wegovy pill, Wegovy pen, Zepbound, and the Foundayo (orforglipron) pill — at the same cash-pay prices as LillyDirect, NovoCare, and TrumpRx, plus a dedicated insurance concierge that handles prior-authorization paperwork and a free coverage checker. The Ro Body membership is $39 for the first month, then as low as $74/month with an annual plan paid upfront; medication is billed separately.

What happens after you choose a provider?

Most online GLP-1 programs follow the same path: intake form → clinician review → prescription if appropriate → pharmacy fills it → ships to you → dosing instructions → follow-ups → refills. What separates a good program from a stressful one is how clearly they tell you who prescribed it, which pharmacy filled it, how to dose it, and how to cancel.

That last one isn't paranoia. The FDA has specifically warned that dosing errors happen when people are unfamiliar with vials or when instructions use units and varying concentrations. Two minutes of double-checking is the cheapest insurance you'll ever buy.

What real customers focus on (and where to check)

The most useful reviews aren't about the number on the scale — they're about the parts you can't see before you buy: how fast support answered, whether dosing instructions were clear, and how cancellation actually went. Check independent sources like Trustpilot, the Better Business Bureau, and your state board for complaints.

Sort reviews into two piles. The first: process — did the clinician answer questions? Did the medication arrive on time and cold? Was cancelling straightforward? That pile is genuinely useful. The second: results — before-and-after stories. Treat those with care. Weight-loss outcomes depend on the person, the dose, and a dozen other factors, and a testimonial can't tell you what will happen for you. Be especially cautious with glowing testimonials on a provider's own marketing site — some carry fine print noting they may use stock images or AI-enhanced content.

How we evaluated these providers

We ranked providers by the quality and verifiability of their pharmacy disclosure — not by medical superiority, and not by what they pay us. The core question was simple: can a cautious shopper find out who fills the prescription, what kind of pharmacy it is, what it costs, whether the FDA caveat is shown, and what's left to verify before paying?

We reviewed each provider's public pages, pricing pages, and pharmacy-disclosure language; the FDA's guidance on compounded GLP-1s; the FDA's February 2026 warning letters and warning-letter database; the FDA's April 2026 proposal on 503B bulk compounding; and federal resources for verifying pharmacies (BeSafeRx) and online pharmacies (NABP). We weighted public pharmacy-name disclosure most heavily, then license-type clarity, then the visibility of the “not FDA-approved” caveat, then pricing transparency, then support and cancellation clarity, then regulatory history.

What our ranking means — and doesn't: a higher spot means cleaner disclosure and easier verification. It does not mean a medication is safer, more effective, or right for you. Only a licensed clinician can decide that.

Affiliate disclosure: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission if you choose a provider through links on this page. That commission never changes the facts we report, the FDA caveats we disclose, or the questions we tell you to ask before paying. We also link to options we earn nothing from when they're the right answer.

Sources

• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA — Dosing errors associated with compounded injectable semaglutide
• FDA — Clarifies policies for compounders as national GLP-1 supply begins to stabilize
• FDA — Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
• FDA — Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
• FDA — Warning Letter, MEDVi, LLC (#721455, 02/20/2026)
• FDA — Warning Letter, Lean Rx, Inc. dba SkinnyRx (#717989, 02/20/2026)
• FDA — Warning Letter, Strut Health, LLC dba Strut (#721448, 02/20/2026)
• FDA — BeSafeRx: Locate a State-Licensed Online Pharmacy
• FDA — Information for Outsourcing Facilities (503B)
• Enhance.MD — FAQ (pharmacy partners and pricing, verified June 2026)
• MEDVi — Partner pharmacies and compounded-drug disclosures (verified June 2026)
• Ro — Weight Loss Program Pricing (verified June 2026)

Frequently asked questions